Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
Cantor Fitzgerald maintains Overweight on ORIC shares, sees upside
Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating.
ETF Daily News22d
Cantor Fitzgerald Predicts ORIC FY2025 Earnings
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...
Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.
Seeking Alpha13d
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data
ORIC Pharmaceuticals' ORIC-533 was promising ... In February last year, analysts at Cantor Fitzgerald noted that the global addressable market for ORC-114 was over $2.5bn, excluding China.
Investing5d
Cantor Fitzgerald maintains Overweight on ORIC stock
On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...